Abstract 264P
Background
Cancer-related cognitive impairment (CRCI), affecting up to 80% of breast cancer (BC) patients, manifests in various cognitive domains such as learning, memory, and concentration. The hippocampus, crucial for these cognitive processes and known to retain its neurogenesis capacity throughout adulthood, is susceptible to morphological alterations due to BC treatment. Recent research highlights the link between physical exercise and neurogenesis. This study aims to investigate CRCI and the potential effects of high-intensity interval training (HIIT) on learning, memory, and concentration function, as well as brain morphology in BC patients undergoing treatment.
Methods
This randomized (1:1) controlled trial allocated early-stage BC patients to either a HIIT intervention group (IG) or a control group (CG). The intervention involved a 12-month supervised HIIT program tailored through cardio-pulmonary exercise testing. Learning, memory, and concentration function were assessed using the California Verbal Learning Test (CVLT) alongside the Wechsler Memory Scale (WMS). Hippocampal volume was evaluated with MRI-based free surfer analysis. Assessments were conducted at baseline and after 12 months.
Results
A total of 69 patients (mean age 50.67 years, SD 10.55; 98.5% female) were recruited. The analysis showed no statistically significant changes in total hippocampal volume in either group (IG: p = 0.25 and p = 0.39; CG: p = 0.25 and p = 0.33). Similarly, no significant changes were observed in the CVLT scores for both groups (IG: p = 0.102; CG: p = 0.059). However, compared to the CG, the IG exhibited significant improvements in the WMS (p < 0.05).
Conclusions
Assessing CRCI in BC patients is challenging. Despite a multimodal approach, we couldn't objectify structural or functional adverse effects on specific cognitive subdomains. Although HIIT exercise during chemotherapy didn't notably impact learning and memory, it did enhance concentration over time. This might suggest that cognitive function in BC patients benefits from exercising.
Clinical trial identification
NCT04789187. Registered on 09 March 2021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Verein zur Forschungsförderung der Krebshilfe OÖ.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
282P - Impact of pembrolizumab on ovarian function in young triple negative breast cancer patients treated with chemo-immunotherapy
Presenter: Anne Perdrix
Session: Poster session 14
283P - Immune-mediated secondary adrenal insufficiency is more commonly found in younger patients undergoing neoadjuvant treatment for early breast cancer
Presenter: Laura Lapuchesky
Session: Poster session 14
284P - Clinical and molecular characteristics of early-stage triple-negative breast cancer (eTNBC) patients with germline pathogenic variants in homologous recombination repair genes
Presenter: Adela Rodriguez Hernandez
Session: Poster session 14
285P - Adherence to endocrine therapy and sexual dysfunction in patients older than 65 years with early estrogen receptor-positive breast cancer
Presenter: Daniele Assad
Session: Poster session 14
286P - Impact of adjuvant endocrine therapy on survival outcomes in female breast cancer patients over 50
Presenter: Hanxiao Zuo
Session: Poster session 14
287P - Cognitive impairment in older breast cancer survivors
Presenter: Sharon Giordano
Session: Poster session 14
289P - Low risk febrile neutropenia: Does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?
Presenter: Jamie Weaver
Session: Poster session 14
290P - Subtype-specific prognostic value of lobular histology in patients with early-stage breast cancer: A nationwide population-based study
Presenter: Guilherme Nader Marta
Session: Poster session 14
291P - Multi-center investigation of a detection model utilizing cfDNA for early-stage breast cancer screening
Presenter: Chao Ni
Session: Poster session 14